Current Research Studies

Cancer – PNOC 016: A Target Validation Study of Fimepinostat in Children and Young Adults with Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG), Recurrent Medulloblastoma, or Recurrent High-Grade Glioma (HGG)

Condition or Therapy:

Diffuse intrinsic pontine glioma (DIPG), recurrent anaplastic astrocytoma, recurrent glioblastoma, recurrent malignant glioma, and recurrent medulloblastoma


Cancer and blood disorders

What is the goal of this study?

The goal of this study is to assess how well fimepinostat works in patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG), medulloblastoma or recurrent high-grade glioma.

Who can join the study?

This study may be a good fit for children and young adults who:

  • Are between 3 and 39 years old and
  • Have newly diagnosed DIPG, recurrent medulloblastoma or recurrent high-grade glioma

What will happen if my child takes part in this study?

You can read more about this study on

Who can I contact for more information?

For more information, call 206-987-2106 or email the study coordinator.

Study Location(s):

Seattle Children's Main Hospital Campus

Principal Investigator:

Dr. Sarah Leary